|
|
|
| Research progress of human epidermal growth factor receptor in metastatic colorectal cancer |
| REN Yanzhen LI Ruixian |
Department of Oncology, Xilin Gol League Central Hospital, Inner Mongolia Autonomous Region, Xilinhot 026000, China
|
|
|
|
Abstract The incidence of human epidermal growth factor receptor 2 (HER2) variants is low in patients with metastatic colon cancer (mCRC), and there is no uniform standard for detection methods. HER2 mutations can lead to resistance to anti-epidermal growth factor receptor-targeted therapy in mCRC. Single anti-HER2-targeted therapy has limited effect, however, dual anti-HER2-targeted therapy such as Trastuzumab combined with Lapatinib or Pertuzumab has shown good anti-tumor efficacy in mCRC. This article aims to review the detection, clinicopathological features, predictive value, and treatment strategies, and prospects of HER2 in mCRC.
|
|
|
|
|
|
[1] Ikoma T，Shimokawa M，Kotaka M，et al. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan [J]. BMC Cancer，2021，21（1）：518.
[2] Dong Z，Kong L，Wan Z，et al. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients [J]. Sci Rep，2019，9（1）：16894.
[3] Guarini C，Grassi T，Pezzicoli G，et al. Beyond RAS and BRAF：HER2，a New Actionable Oncotarget in Advanced Colorectal Cancer [J]. Int J Mol Sc，2021，22（13）：6813.
[4] Sartore-Bianchi A，Amatu A，Porcu L，et al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer [J]. Oncologist，2019，24（10）：1395-1402.
[5] Cremolini C，Morano F，Moretto R，et al. Negative hyper-selection of metastatic colorectal cancer patients for anti- EGFR monoclonal antibodies：the PRESSING case-control study [J]. Ann Oncol，2017，28（12）：3009-3014.
[6] Grassilli E，Cerrito MG. Emerging actionable targets to treat therapy-resistant colorectal cancers [J]. Cancer Drug Resist，2022，5（1）：36-63.
[7] Valtorta E，Martino C，Sartore-Bianchi A，et al. Assessment of a HER2 scoring system for colorectal cancer：results from a validation study [J]. Mod Pathol，2015，28（11）：1481-1491.
[8] Meric-Bernstam F，Hurwitz H，Raghav KPS，et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer（MyPathway）：an updated report from a multicentre，open-label，phase 2a，multiple basket study [J]. Lancet Oncol，2019，20（4）：518-530.
[9] Nakamura Y，Taniguchi H，Ikeda M，et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer：SCRUM-Japan GI-SCREEN and GOZILA studies [J]. Nat Med，2020，26（12）：1859-1864.
[10] Shimada Y，Yagi R，Kameyama H，et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer [J]. Hum Pathol，2017，66：1-9.
[11] Liu F，Ren C，Jin Y，et al. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer [J]. Virchows Arch，2020，476（3）：391-398.
[12] Strickler JH，Yoshino T，Graham RP，et al. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer：A Review [J]. JAMA Oncol，2022，8（5）：760-769.
[13] Achalla LSV，Shinde RK，Jogdand S，et al. Review of the Role of HER2/neu in Colorectal Carcinomas [J]. Cureus，2022，14（5）：e25409.
[14] Shan L，Lv Y，Bai B，et al. Variability in HER2 expression between primary colorectal cancer and corresponding metastases [J]. J Cancer Res Clin Oncol，2018，144（11）：2275-2281.
[15] Kavuri SM，Jain N，Galimi F，et al. HER2 activating mutations are targets for colorectal cancer treatment [J]. Cancer Discov，2015，5（8）：832-841.
[16] Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer [J]. Nature，2012，487（7407）：330-337.
[17] Qiu MZ，He CY，Yang XH，et al. Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma [J]. Oncologist，2021，26（7）：e1161-e1170.
[18] Saygin I，Cakir E. The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI [J]. Indian J Pathol Microbiol，2022，65（2）：336- 342.
[19] Nowak JA. HER2 in Colorectal Carcinoma：Are We There yet? [J]. Surg Pathol Clin，2020，13（3）：485-502.
[20] Rivera M，Fichtner I，Wulf-Goldenberg A，et al. Patient- derived xenograft （PDX） models of colorectal carcinoma （CRC） as a platform for chemosensitivity and biomarker analysis in personalized medicine [J]. Neoplasia，2021，23（1）：21-35.
[21] Sartore-Bianchi A，Trusolino L，Martino C，et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory，KRAS codon 12/13 wild-type，HER2- positive metastatic colorectal cancer （HERACLES）：a proof-of-concept，multicentre，open-label，phase 2 trial [J]. Lancet Oncol，2016，17（6）：738-746.
[22] Morano F，Corallo S，Lonardi S，et al. Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy [J]. J Clin Oncol，2019，37（33）：3099- 3110.
[23] Huang W，Chen Y，Chang W，et al. HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti- EGFR therapy in colorectal cancer [J]. J Cancer Res Clin Oncol，2021.published online EpubJun 22.
[24] Luca T，Barresi V，Privitera G，et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells [J]. Cell Prolif，2014，47（5）：435-47.
[25] Leto SM，Sassi F，Catalano I，et al. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas [J]. Clin Cancer Res，2015，21（24）：5519-5531.
[26] Hainsworth JD，Meric-Bernstam F，Swanton C，et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles：Results From MyPathway，an Open-Label，Phase IIa Multiple Basket Study [J]. J Clin Oncol，2018，36（6）：536-542.
[27] Gupta R，Garrett-Mayer E，Halabi S，et al. Pertuzumab plus trastuzumab （P+T） in patients （Pts） with colorectal cancer （CRC） with ERBB2 amplification or overexpression：Results from the TAPUR Study [J]. J Clin Oncol，2020，38：4s（suppl；abstr 132）.
[28] Nakamura Y，Okamoto W，Kato T，et al. TRIUMPH：Pri- mary efficacy of a phase Ⅱ trial of trastuzumab （T） and pertuzumab （P） in patients （pts） with metastatic colorectal cancer （mCRC） with HER2 （ERBB2） amplification （amp） in tumour tissue or circulating tumour DNA （ctDNA）：A GOZILA sub-study [J]. Ann Oncol，2019，30（suppl 5）：198-252.
[29] Sartore-Bianchi A，Lonardi S，Martino C，et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer：the phase Ⅱ HERACLES-B trial [J]. ESMO Open，2020，5（5）：e000911.
[30] Li W，Chang J，Xu M，Zhu X. Anti-HER2 therapy with pyrotinib and trastuzumab in refractory HER2-positive metastatic colorectal cancer：a preliminary report from HER2-FUSCC-G study [J]. J Clin Oncol，2022，44s（suppl；abstr 97）.
[31] Strickler JH，Zemla T，Ou F，et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer （mCRC）：Initial results from the MOUN- TAINEER trial [J]. Ann Oncol，2019，30（suppl 5）：198-252.
[32] Tsurutani J，Iwata H，Krop I，et al. Targeting HER2 with Trastuzumab Deruxtecan：A Dose-Expansion，Phase Ⅰ Study in Multiple Advanced Solid Tumors [J]. Cancer Discov，2020，10（5）：688-701.
[33] Siena S，Di Bartolomeo M，Raghav K，et al. Trastuzumab deruxtecan （DS-8201） in patients with HER2-expressing metastatic colorectal cancer （DESTINY-CRC01）：a multicentre，open-label，phase 2 trial [J]. Lancet Oncol，2021， 22（6）：779-789.
[34] Benson AB，Venook AP，Al-Hawary MM，et al. Colon Cancer，Version 2.2021，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2021，19（3）：329- 359. |
|
|
|
